(12) International Application Status Report

Received at International Bureau: 20 May 2015 (20.05.2015)

Information valid as of: 08 February 2016 (08.02.2016)

Report generated on: 23 February 2020 (23.02.2020)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2015/17315419 November 2015 (19.11.2015) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/EP2015/06025708 May 2015 (08.05.2015) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
1408387.7 (GB)12 May 2014 (12.05.2014) Priority document received (not in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 31/167 (2006.01); A61K 31/58 (2006.01); A61K 9/00 (2006.01); A61P 11/00 (2006.01); A61P 11/08 (2006.01); A61P 43/00 (2006.01)

(71) Applicant(s):
TEVA PHARMACEUTICALS EUROPE B.V. [NL/NL]; Piet Heinkade 107 NL-1019GM Amsterdam (NL) (for all designated states)

(72) Inventor(s):
ULLMANN, Michiel; Teva Pharmaceuticals Europe B.V. Piet Heinkade 107 NL-1019GM Amsterdam (NL)

(74) Agent(s):
COTTAM, David, William; Teva UK Ltd Global IP Group Field House Station Approach Harlow Essex CM20 2FB (GB)

(54) Title (EN): COMBINATIONS OF FORMOTEROL AND BUDESONIDE FOR THE TREATMENT OF COPD
(54) Title (FR): COMBINAISONS DE FORMOTÉROL ET DE BUDÉSONIDE POUR LE TRAITEMENT D'UNE BPCO

(57) Abstract:
(EN): This invention provides a fixed-dose composition comprising formoterol or a pharmaceutically acceptable salt thereof and budesonide, for use in the long-term treatment of COPD and the treatment of acute exacerbations of COPD, wherein the composition is administered as a maintenance dose for the long-term treatment of COPD and pro re nata (p.r.n.) as a rescue medication for the treatment of acute exacerbations of COPD.
(FR): La présente invention concerne une composition à dose fixe comprenant du formotérol ou un sel pharmaceutiquement acceptable de celui-ci et du budésonide, destinée à être utilisée dans le traitement à long terme d'une broncho-pneumopathie chronique obstructive (BPCO) et le traitement d'exacerbations aiguës de la BPCO, ladite composition étant administrée sous forme de dose d'entretien pour le traitement à long terme d'une BPCO et pro re nata (p.r.n.) en tant que médicament de secours pour le traitement d'exacerbations aiguës de la BPCO.

International search report:
Received at International Bureau: 15 June 2015 (15.06.2015) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM